Regulatory considerations of a growing pharmaceutical company: a UK/US comparison of the generics industry

By Jenny Lakin2023-09-01T13:29:00

Generics must demonstrate equivalence to the originator product to gain regulatory approval and market entry. There is a large market for generics that is predicted to continue to grow. The individual price of generics is lower than the originator, nevertheless manufacturers can avoid large development costs to bring generics to ...

How to read this journal article

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

REGISTER FOR FREE

1. Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

Create your own library to save your favourite content.
Sign up for Regulatory Rapporteur email newsletters.

Create a free account

Members login

2. Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.

JOIN TOPRA

3. TOPRA membership

Become a TOPRA member and join our global regulatory affairs community.

Great savings on our events and training.
Be part of our dynamic international community.
Contribute to the profession.
Grow your skills and knowledge.
Take your career to the next level.

Become a member